REGN — Regeneron Pharmaceuticals
In 2026 Q2, 7 of the 140 tracked hedge funds reported a position in Regeneron Pharmaceuticals (REGN), worth $200.38M combined. Over the quarter 6 opened or added, 5 trimmed or exited.
Hedge fund holders, 2026 Q2
| Fund | Value | Portfolio % | Change |
|---|---|---|---|
| Renaissance | $92.42M | 0.13% | +121.9% |
| VanEck | $40.74M | 0.02% | +4.4% |
| Quadrature | $30.60M | 0.26% | +163.8% |
| ARS | $28.36M | 1.20% | +0.5% |
| Augustine | $4.29M | 0.87% | +53.7% |
| IMC | $3.49M | 0.03% | NEW |
| Polymer | $481.37K | 0.07% | -44.1% |
All stocks · Quarterly Trends · Hedge Fund Tracker
Source: SEC EDGAR 13F filings, reported as of quarter end and filed up to 45 days later. Not investment advice.